Jun 25 |
Zevra Therapeutics Expands Executive Leadership Team
|
Jun 19 |
Breakeven On The Horizon For Zevra Therapeutics, Inc. (NASDAQ:ZVRA)
|
Jun 18 |
Zevra Therapeutics Transitions to Orsini as the Specialty Pharmacy Provider for OLPRUVA® (sodium phenylbutyrate), a Treatment for Certain Urea Cycle Disorders
|
Jun 4 |
Zevra Therapeutics files for $350M mixed shelf
|
Jun 3 |
Zevra Therapeutics Announces Positive Final Results from Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at SLEEP 2024 Annual Meeting
|
May 30 |
Retail investors account for 59% of Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) ownership, while institutions account for 28%
|
May 9 |
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Q1 2024 Earnings Call Transcript
|
May 9 |
Zevra Therapeutics to Participate at Upcoming Investor Events
|
May 9 |
Zevra Therapeutics First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
|
May 9 |
Zevra Therapeutics Inc (ZVRA) (Q1 2024) Earnings Call Transcript Highlights: Navigating ...
|